Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Cash-to-Debt : 0.10 (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Parnell Pharmaceuticals Holdings's cash to debt ratio for the quarter that ended in Dec. 2018 was 0.10.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Parnell Pharmaceuticals Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2018.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's Cash-to-Debt or its related term are showing as below:

PARNF's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.93
* Ranked among companies with meaningful Cash-to-Debt only.

Parnell Pharmaceuticals Holdings Cash-to-Debt Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Parnell Pharmaceuticals Holdings Cash-to-Debt Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Cash-to-Debt

Get a 7-Day Free Trial

4.85

0.32

0.24

0.07

0.10

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Cash-to-Debt	Get a 7-Day Free Trial			4.85	0.32	0.24	0.07	0.10

Competitive Comparison of Parnell Pharmaceuticals Holdings's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Cash-to-Debt falls into.

Parnell Pharmaceuticals Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Parnell Pharmaceuticals Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2018 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.155	/	(0.007	+	32.282)
	=	0.10

Parnell Pharmaceuticals Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2018 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.155	/	(0.007	+	32.282)
	=	0.10

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Parnell Pharmaceuticals Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.